aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
viernes, 28 de junio de 2024
FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test Test Enables Single-Visit Testing and Treatment for Hepatitis C
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-point-care-hepatitis-c-rna-test
Today, the U.S. FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away.
Although a cure for hepatitis C is available, many people with the potentially deadly disease are not aware that they have it and do not receive treatment. This is partly because hepatitis C testing has been a lengthy process before results are available and requires follow-up appointments. But now, it will be possible to obtain a test result and start a course of treatment at the same health visit.
https://www.nibib.nih.gov/about-nibib/directors-corner
No hay comentarios:
Publicar un comentario